William Blair restated their outperform rating on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Free Report) in a research note issued to investors on Wednesday morning,RTT News reports.
Separately, UBS Group lifted their target price on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, January 27th.
Get Our Latest Research Report on Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited American Depositary Shares Stock Performance
Telix Pharmaceuticals Limited American Depositary Shares Company Profile
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Further Reading
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- Investing In Automotive Stocks
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- What to Know About Investing in Penny Stocks
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
